Sub menu

 
 

ENOXAPO (Apotex Pty Ltd)

Product name
ENOXAPO
Sponsor
Apotex Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
142 working days (255)
Active ingredients
enoxaparin sodium
Registration type
NCE/NBE
Indication

ENOXAPO (solution for injection) is indicated for the prevention of thromboembolic disorders of venous origin in patients undergoing orthopaedic and general surgery.

ENOXAPO is indicated for the prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness.

ENOXAPO is indicated for the prevention of thrombosis in extra-corporeal circulation during haemodialysis.

ENOXAPO is indicated for the treatment of established deep vein thrombosis.

ENOXAPO is indicated for the treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.

ENOXAPO is indicated for the treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI).

Help us improve the Therapeutic Goods Administration site